A Prospective Economic Analysis NCIC CTG CLC.2/ALLIANCE A041202: A Randomized Phase III CLL Study of Bendamustine Plus Rituximab Versus Ibrutinib Plus Rituximab Versus Ibrutinib Alone in Untreated Older Patients (≥65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 30 Mar 2017
At a glance
- Drugs Ibrutinib (Primary) ; Bendamustine; Rituximab
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 28 Mar 2016 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.
- 22 Mar 2016 Status changed from not yet recruiting to recruiting, according to ClinicalTrials.gov record.